相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Discordant GH and IGF-1 Results in Treated Acromegaly: Impact of GH Cutoffs and Mean Values Assessment
Claudia Campana et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
Pituitary-Tumor Endocrinopathies
Shlomo Melmed
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study
Stephan Petersenn et al.
PITUITARY (2020)
Molecular profiling for acromegaly treatment: a validation study
Manel Puig-Domingo et al.
ENDOCRINE-RELATED CANCER (2020)
Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly
Eva C. Coopmans et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Multidisciplinary management of acromegaly: A consensus
Andrea Giustina et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2020)
Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update
Monica R. Gadelha et al.
ENDOCRINE REVIEWS (2019)
E-cadherin expression is associated with somatostatin analogue response in acromegaly
Eva Venegas-Moreno et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2019)
Acromegaly
Annamaria Colao et al.
NATURE REVIEWS DISEASE PRIMERS (2019)
Pituitary magnetic resonance imaging predictive role in the therapeutic response of growth hormone-secreting pituitary adenomas
Fabio Tortora et al.
GLAND SURGERY (2019)
Paradoxical GH Increase During OGTT Is Associated With First-Generation Somatostatin Analog Responsiveness in Acromegaly
Carla Scaroni et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Signs and symptoms of acromegaly at diagnosis: the physician's and the patient's perspectives in the ACRO-POLIS study
Philippe Caron et al.
ENDOCRINE (2019)
Laboratory investigations in the diagnosis and follow-up of GH-related disorders
Katharina Schilbach et al.
ARCHIVES OF ENDOCRINOLOGY METABOLISM (2019)
How are growth hormone and insulin-like growth factor-1 reported as markers for drug effectiveness in clinical acromegaly research? A comprehensive methodologic review
Michiel J. van Esdonk et al.
PITUITARY (2018)
Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas
Sema Ciftci Dogansen et al.
PITUITARY (2018)
A Consensus Statement on acromegaly therapeutic outcomes
Shlomo Melmed et al.
NATURE REVIEWS ENDOCRINOLOGY (2018)
Epidemiology of acromegaly in Italy: analysis from a large longitudinal primary care database
Federico Gatto et al.
ENDOCRINE (2018)
Comorbidities, treatment patterns and cost-of-illness of acromegaly in Sweden: a register-linkage population-based study
Eva Lesen et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2017)
Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry
Luigi Maione et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2017)
T2-weighted MRI signal intensity as a predictor of hormonal and tumoral responses to somatostatin receptor ligands in acromegaly: a perspective
Iulia Potorac et al.
PITUITARY (2017)
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
Annamaria Colao et al.
PITUITARY (2016)
Assessing size of pituitary adenomas: a comparison of qualitative and quantitative methods on MR
Benjamin M. Davies et al.
ACTA NEUROCHIRURGICA (2016)
T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly
Iulia Potorac et al.
ENDOCRINE-RELATED CANCER (2016)
Incidence and prevalence of acromegaly in a large US health plan database
Tanya Burton et al.
PITUITARY (2016)
Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly
Ansgar Heck et al.
ENDOCRINE (2016)
Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center
Susanna Bacigaluppi et al.
ENDOCRINE (2016)
Pros and cons in endocrine practice: pre-surgical treatment with somatostatin analogues in acromegaly
Marco Losa et al.
ENDOCRINE (2016)
MRI T2 characteristics in somatotroph adenomas following somatostatin analog treatment in acromegaly
Ansgar Heck et al.
ENDOCRINE (2016)
Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences
Iulia Potorac et al.
ENDOCRINE-RELATED CANCER (2015)
Tumor Shrinkage With Lanreotide Autogel 120 mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial
Philippe J. Caron et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Acromegaly: An Endocrine Society Clinical Practice Guideline
Laurence Katznelson et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Somatostatin receptor ligands and resistance to treatment in pituitary adenomas
Daniel Cuevas-Ramos et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2014)
Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern
Leandro Kasuki et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2013)
Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in Somatotroph Adenomas Assessed by Monoclonal Antibodies Was Reduced by Octreotide and Correlated With the Acute and Long-Term Effects of Octreotide
Olivera Casar-Borota et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Immunoreactivity Score Using an Anti-sst2A Receptor Monoclonal Antibody Strongly Predicts the Biochemical Response to Adjuvant Treatment with Somatostatin Analogs in Acromegaly
Federico Gatto et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Changes in acromegaly treatment over four decades in Spain: analysis of the Spanish Acromegaly Registry (REA)
Gemma Sesmilo et al.
PITUITARY (2013)
Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience
Jessica Brzana et al.
PITUITARY (2013)
Novel pathway for somatostatin analogs in patients with acromegaly
Monica R. Gadelha et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2013)
Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins
Federico Gatto et al.
CLINICAL ENDOCRINOLOGY (2012)
Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly
Ansgar Heck et al.
CLINICAL ENDOCRINOLOGY (2012)
Pre-surgical treatment with somatostatin analogues in patients with acromegaly: The case against
M. Losa et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2012)
Pre-surgical treatment with somatostatin analogues in patients with acromegaly: The case for
D. Ferone et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2012)
Resistance to Somatostatin Analogs in Acromegaly
Annamaria Colao et al.
ENDOCRINE REVIEWS (2011)
Magnetic Resonance Imaging as a Predictor of Response to Somatostatin Analogs in Acromegaly after Surgical Failure
Manel Puig-Domingo et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
The Expression of E-Cadherin in Somatotroph Pituitary Adenomas Is Related to Tumor Size, Invasiveness, and Somatostatin Analog Response
Stine Lyngvi Fougner et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant?
Pamela U. Freda
CLINICAL ENDOCRINOLOGY (2009)
The octreotide test dose is not a reliable predictor of the subsequent response to somatostatin analogue therapy in patients with acromegaly
A Pokrajac et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006)
Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly
WW de Herder et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2005)
Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly
NR Biermasz et al.
GROWTH HORMONE & IGF RESEARCH (2005)
The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly
N Karavitaki et al.
CLINICAL ENDOCRINOLOGY (2005)
Systemic complications of acromegaly: Epidemiology, pathogenesis, and management
A Colao et al.
ENDOCRINE REVIEWS (2004)
Comparison of growth hormone-producing and non-growth hormone-producing pituitary adenomas: Imaging characteristics and pathologic correlation
A Hagiwara et al.
RADIOLOGY (2003)
分享论文
